Effective interferon therapy for chronic hepatitis C patients with low viral loads

Hepato-Gastroenterology

Volumn 50, Issue 51, 2003, Pages 817-820

  Fujiyama, Shigetoshi ^a   Chikazawa, Hideto ^a   Honda, Yoshikazu ^a   Tomita, Kimio ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; HCV RNA; Hypervariable region 1; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; TIME SERIES ANALYSIS; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MUTATION; RNA, VIRAL; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRAL PROTEINS;

EID: 0038577477     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kanai K, Kako M, Okamoto H: HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339:1543.
2. Davis GL: Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21:1-3.
3. Toyoda H, Kumada T, Nakano S, Takeda I, SugIyama K, Osada T, Kirlyama S, Sone Y, Kinoshita M, Hadama T: Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 1997; 26:6-13.
4. Koizumi K, Enomoto N, Kurosaki M, Murakami T, Izumi N, Marumo F, Sato C: Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22:30-35.
5. Wiley TE, Briedi L, Lam N, Layden TJ: Early HCV RNA values after interferon predict response. Dig Dis Sci 1998; 43:2169-2172.
6. Karino Y, Toyota J, Matsushima T, Higashino K, Sato T, Ohmura T, Suga T, Okuuchi Y, Matsushima T: Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997; 92:61-65.
7. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M: Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18:16-20.
8. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y. Typing hepatitis C virus by polymeric chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-679.
9. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, et al: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19:1321-1324.
10. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C: Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994; 75:1361-1369.
11. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
13. Moriya T, Koyama T, Tanaka J, Mishiro S, Yoshizawa H: Epidemiology of hepatitis C virus in Japan. Intervirology 1999; 42:153-158.
14. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Nakamura I, Murashima N, Kumada H, Kawanishi M: Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-1130.
15. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshida K, Kakumu S, Iijima A, Urushihara A, Kiyosawa K, Okuda M, Hino K, Okita K: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27:1394-1402.
16. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda M, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y: Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129:94-99.
17. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sara M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131:174-181.
18. Shiell A, Brown S, Farrell GC: Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999; 171:189-193.
19. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Matsumoto T, Hashimoto M, Kobayashi M, Kanda M, Morinaga T: Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 1995; 23:648-653.
20. Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, Okuda M, Okita K: Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000; 7:36-42.